NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study ...
Vivani Medical, Inc. (NASDAQ:VANI), on Wednesday, released preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight management in obese and overweight ...
It was only a matter of time until the GLP-1 receptor agonist drugs like Ozempic and Wegovy were superseded, and now it looks ...
NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration ... of GLP-1 therapy “Products containing semaglutide generated $25 billion in 2024 and demand ...
NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration ... its subdermal semaglutide implant under development for chronic weight management in obese ...
Shares of the health and wellness platform operator skyrocketed more than 670% between Jan. 1, 2024, and Feb. 19, 2025.
NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration with expected ... today announced promising preclinical data for NPM-139, its subdermal semaglutide ...
Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback